364 results on '"Del Galdo F"'
Search Results
2. OP0296 ARRHYTHMIC BURDEN, MYOCARDIAL MARKERS, AND LONG-TERM SURVIVAL IN DISTINCT CARDIAC MAGNETIC RESONANCE SUBSETS OF SYSTEMIC SCLEROSIS
3. POS0230 CHARACTERISTICS AND DISEASE COURSE OF SSc-ILD PATIENTS WITH GASTROESOPHAGEAL REFLUX – AN ANALYSIS OF THE EUSTAR COHORT
4. POS0832 IMMUNOSUPPRESSION VERSUS COMBINATION OF IMMUNOSUPPRESSION AND ORAL GLUCOCORTICOIDS FOR SKIN FIBROSIS IN EARLY DIFFUSE SYSTEMIC SCLEROSIS PATIENTS. A TARGET TRIAL EMULATION STUDY FROM THE EUSTAR DATABASE
5. AB1152 BILE ACID INDUCED CELLULAR AND MOLECULAR CHANGES OF OESOPHAGEAL EPITHELIAL CELLS MAY CONTRIBUTE TO THE PATHOGENESIS OF SYSTEMIC SCLEROSIS. A PILOT IN VITRO STUDY
6. OP0225 CHANGES IN TREATMENT PATTERNS AND THEIR INFLUENCE ON THE OUTCOME OF SYSTEMIC SCLEROSIS-INTERSTITIAL LUNG DISEASE (SSc-ILD) PATIENTS: AN EUSTAR ANALYSIS
7. POS1419 EULAR SCLEROID AS COMPREHENSIVE PATIENT REPORTED OUTCOME IN SYSTEMIC SCLEROSIS: LONGITUDINAL VALIDATION OF CONTENT VALIDITY AND SENSITIVITY TO CHANGE
8. POS0404 MRI DAVIX INDEX SHOWS BIOLOGICAL FACE VALIDITY: CYTOFLUORIMETRY ANALYSIS TO UNCOVER THE RELATIONSHIP BETWEEN VASCULAR DAMAGE AND ENDOTHELIAL CELL POPULATIONS IN SYSTEMIC SCLEROSIS PATIENTS AND UNDERPIN A CELLULAR PHENOTYPING OF PATIENTS
9. POS0425 SUBCLINICAL LOSS OF LUNG VOLUMES IN VERY EARLY SSc: EVIDENCE FROM THE VEDOSS DATABASE
10. AB1150 TYPE I INTERFERON ACTIVATION OF MONOCYTES IN SYSTEMIC SCLEROSIS IS CGAS-STING DEPENDENT AND CAN BE DIRECTLY INDUCED BY DERMAL FIBROBALSTS: A PROMISING THERAPEUTIC TARGET
11. POS0823 MULTI-CENTRE VALIDATION OF THE PASTUL QUESTIONNAIRE FOR SELF-ASSESSMENT OF SKIN SEVERITY IN SYSTEMIC SCLEROSIS
12. OP0314 INTERFERON SCORE AS A NOVEL TRIAL ENRICHMENT TOOL TO PREDICT CLINICAL OUTCOMES IN PATIENTS WITH LIMITED CUTANEOUS SYSTEMIC SCLEROSIS
13. OP0013 ANTI-Ro/SSA ANTIBODIES ARE PREDICTIVE OF A MORE SEVERE LUNG INVOLVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS: A STUDY FROM THE EUSTAR HDATABASE
14. Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research
15. Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher/European Scleroderma Trials and Research group (EUSTAR) survey
16. POS1260 SYSTEMATIC LITERATURE REVIEW FOR THE 2023 UPDATE OF EULAR RECOMMENDATIONS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS
17. AB0808 A PROOF OF BIOLOGICAL CONCEPT TRIAL OF CM101 TO TARGET CCL24 IN SYSTEMIC SCLEROSIS: A BIOMARKER INFORMED, PRECISION MEDICINE APPROACH
18. OP0238 IMMUNOSUPPRESSION WITH TARGETED DMARDS REDUCES MORBIDITY AND MORTALITY IN PRE-CAPILLARY PULMONARY HYPERTENSION ASSOCIATED WITH SYSTEMIC SCLEROSIS: A EUSTAR ANALYSIS
19. POS1336 MRI DIGITAL ARTERY VOLUME INDEX (DAVIX©) AS QUANTITATIVE, CONTINUOUS IMAGING OUTCOME MEASURE OF VASCULAR DISEASE IN SYSTEMIC SCLEROSIS
20. POS1257 CCL24 SERUM CONCENTRATION PREDICTS BOTH VASCULAR AND FIBROTIC COMPLICATIONS IN SYSTEMIC SCLEROSIS
21. OP0113 THE BETA SECRETASE BACE1 DRIVES SYSTEMIC SCLEROSIS FIBROBLASTS ACTIVATION THROUGH Β-CATENIN AND NOTCH SIGNALLING
22. OP0234 2023 UPDATE OF EULAR RECOMMENDATIONS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS
23. POS0627 BLOOD-BASED PROTEIN BIOMARKERS ARE ASSOCIATED WITH SUBCLINICAL CARDIOVASCULAR ABNORMALITIES AS DEFINED BY CARDIOVASCULAR MAGNETIC RESONANCE IMAGING IN SYSTEMIC SCLEROSIS (SSc) PATIENTS
24. POS1258 RESULTS FROM A NOMINAL GROUP TECHNIQUE EXERCISE FOR THE CREATION OF A COMBINED RESPONSE INDEX FOR LIMITED CUTANEOUS SYSTEMIC SCLEROSIS: THE CRISTAL PROJECT
25. POS0338 DEVELOPMENT AND VALIDATION OF RANKED COMPOSITE IMPORTANT DIFFERENCE (RCID) SCORE IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
26. POS0141 APPLICATION OF CRISS SCORE, REVISED CRISS SCORE AND RCID SCORE IN PATIENTS WITH JUVENILE SYSTEMIC SCLEROSIS
27. POS0146 BIOSAMPLES FROM VEDOSS PATIENTS SHOW CLASSIC PATHOLOGICAL SIGNS OF SCLERODERMA:OPPORTUNITY FOR A BIOLOGICAL DIAGNOSIS OF DISEASE
28. AB0881 CLINICAL TRAJECTORIES OF MULTIFACTORIAL HAND FUNCTION DETERIORATION IN SYSTEMIC SCLEROSIS
29. 1577 MicroRNA biomarkers in interstitial skin fluid for preclinical diagnosis of scleroderma
30. More to B: the growing evidence to inform targeting B cells in scleroderma
31. Late Skin Fibrosis in Systemic Sclerosis: A Study from the EUSTAR Cohort
32. Use of optical coherence tomography for the diagnosis of preclinical lesions of circumscribed palmar hypokeratosis
33. POS0140 PREDICTING OUTCOMES IN SYSTEMIC SCLEROSIS: STRATIFICATION BY AUTO-ANTIBODIES OUTPERFORMS CUTANEOUS SUBSETTING IN THE EUSTAR COHORT
34. POS0893 FACTORS TO CONSIDER FOR MEASURING THE EFFECT OF LUNG FUNCTION ON PATIENT REPORTED OUTCOMES IN SYSTEMIC SCLEROSIS PATIENTS: ANALYSIS OF THE EUSTAR DATABASE.
35. AB0142 EVIDENCE OF TYPE I INTERFERON ACTIVATION DURING VASCULAR MANIFESTATIONS OF SYSTEMIC SCLEROSIS
36. POS0467 DERSIMELAGON, A NOVEL ORAL MELANOCORTIN 1 RECEPTOR AGONIST, DEMONSTRATES DISEASE-MODIFYING EFFECTS IN PRECLINICAL MODELS OF SYSTEMIC SCLEROSIS
37. POS0383 CLINICAL CHARACTERISTICS AND PROGNOSIS OF PATIENTS WITH SYSTEMIC SCLEROSIS SINE SCLERODERMA: DATA FROM THE INTERNATIONAL EUSTAR DATABASE.
38. POS0876 SERUM INTERFERON SCORE PREDICTS SEVERITY OF PATIENT REPORTED HAND DISABILITY IN SYSTEMIC SCLEROSIS
39. POS0489 CCL24 SERUM CONCENTRATION CORRELATES WITH DISEASE ACTIVITY AND WORSE PROGNOSIS IN DIFFUSE CUTANEOUS SSc: A PROMISING BIOLOGICAL TARGET TO PREVENT DISEASE PROGRESSION
40. POS0868 THE DEVELOPMENT OF THE LINEAR CRISS; A CLINICAL AND PATIENT MEANINGFUL ANCHOR TO THE ACR-CRISS IN SCLERODERMA.
41. Oral 11β-HSD1 inhibitor AZD4017 improves wound healing and skin integrity in adults with type 2 diabetes mellitus: a pilot randomized controlled trial
42. CLINICAL CHARACTERISTICS AND PROGNOSIS OF PATIENTS WITH SYSTEMIC SCLEROSIS SINE SCLERODERMA: DATA FROM THE INTERNATIONAL EUSTAR DATABASE
43. Cardiovascular outcomes in systemic sclerosis with abnormal cardiovascular MRI and serum cardiac biomarkers
44. First pilot study of extracellular volume MRI measurement in peripheral muscle of systemic sclerosis patients suggests diffuse fibrosis
45. Retrospective comparison of drug treatment of joint involvement in systemic sclerosis: 6.18
46. PRS3 Joint Modelling of Forced Vital Capacity Decline and Time to Hospitalization Outcomes in Systemic Sclerosis-Associated Interstitial Lung Disease
47. A role for caveolin-1 in desmoglein binding and desmosome dynamics
48. OP0269 A COMBINED CLINICAL AND BIOMARKER ALGORITHM TO PREDICT FVC DECLINE IN SYSTEMIC SCLEROSIS ASSOCIATED INTERSTITIAL LUNG DISEASE: RESULTS FROM AN INTERNATIONAL MULTICENTRE OBSERVATIONAL COHORT
49. POS0319 PERFORMANCE OF PATIENT REPORTED OUTCOMES (PROs) IN SCLERODERMA PATIENTS WITH REDUCED LUNG FUNCTION IN AN OBSERVATIONAL COHORT
50. POS0425 INCREASED KERATIN 9 EXPRESSION IN SYSTEMIC SCLEROSIS SKIN IS DRIVEN BY THE lncRNA HOTAIR FROM FIBROBLAST DERIVED EXOSOMES
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.